Photo of Barry S. Coller

Barry S. Coller

  • CLINICAL PROFESSOR Medicine
Print ProfilePrint Profile

Certifications

  • Hematology

  • Hematology

  • American Board of Internal Medicine

Education

  • MD, New York University

  • Residency, Internal Medicine
    Bellevue Hospital Center

  • Residency, Internal Medicine
    Bellevue Hospital Center

  • Fellowship, Hem-Clin Pathology
    National Institute Health

Biography

    When blood vessels break, platelets stop the bleeding by adhering to the damaged vessel walls. They then aggregate with each other and facilitate thrombin production and fibrin deposition, both of which are key components of blood coagulation. Dr. Coller’s research focuses on molecular interactions between blood cells and blood vessels as they relate to platelet physiology, thrombosis, vascular biology and adhesion phenomena, with the ultimate goal of developing new therapies for thrombosis diseases such as heart attack and stroke.

    Because platelets play a vital role in blood coagulation, deficiencies in their numbers or function can result in excessive bleeding. But when platelets adhere to and aggregate on blood vessels narrowed by atherosclerosis, they can close off the blood vessel and cause a myocardial infarction (heart attack) or stroke.

    By studying the receptors responsible for platelet aggregation, and patients who genetically lack the receptors, Dr. Coller established the platelet αIIbβ3 (GPIIb/IIIa) receptor as an important target for antithrombotic therapy. This led him to develop monoclonal antibodies to the αIIbβ3 receptor that inhibit platelet aggregation. Working with scientists at Centocor, Dr. Coller helped develop one of these antibodies into the drug abciximab, which was approved in 1994 to prevent ischemic complications of percutaneous coronary interventions, such as stent placement in patients with myocardial infarction and related conditions. More than two and a half million patients worldwide have been treated with abciximab.

    Current research in Dr. Coller’s lab focuses on multiple areas of platelet physiology. One of those areas is the genetic disorder Glanzmann thrombasthenia, which produces hemorrhage as a result of an abnormality of the αIIbβ3 receptor. Dr. Coller and his lab members are studying the precise genetic and protein abnormalities responsible for the disease.

    Other areas of blood and platelet physiology that the lab is studying include:

    1) Integrin structure and activation: Integrins (including αIIbβ3) are transmembrane glycoprotein receptors. Through site-directed mutagenesis, molecular dynamics, electron microscopy, and x-ray crystallography studies, the lab is studying the mechanisms by which the receptors undergo a transition from an inactive to an active conformation with high affinity for ligand.

    2) High throughput screening: The Coller lab has identified a single compound out of more than 33,000 tested that inhibits ligand binding to αIIbβ3. This lead is being pursued by chemical modifications to enhance affinity and as a structural probe of the αIIbβ3 ligand binding pocket. The compound has anti-thrombotic activity and is rapidly absorbed after oral administration to dogs. A new screen with more than 350,000 compounds is now planned.

    3) Platelet TGF-β1: The Coller lab discovered that platelet TGF-β1, a potent modifier of gene transcription and cellular behavior, can be activated by shear forces, and studies are under way to assess the biologic significance of this finding in model systems.

    4) Murine models of myocardial infarction: To better study myocardial infarction in mice, the Coller lab is using ultrasound-guided techniques to induce myocardial infarctions that are less traumatic than current surgical methods.

    CAREER

    Dr. Coller received his B.A. from Columbia University in 1966 and his M.D. from New York University School of Medicine in 1970. He completed his residency in internal medicine at Bellevue Hospital in New York City and received advanced training in hematology and clinical pathology at the National Institutes of Health. He was at Stony Brook University from 1976 to 1993, and from 1993 to 2001 he servedas a professor of medicine and chairman of the department of medicine at Mount Sinai School of Medicine. Dr. Coller came to Rockefeller in 2001 as the first David Rockefeller Professor, head of the Laboratory of Blood and Vascular Biology, physician in chief of The Rockefeller University Hospital and vice president for medical affairs. Dr. Coller also serves as principal investigator of the university’s Clinical and Translational Science Award and director of The Rockefeller University Center for Clinical and Translational Science.

    Dr. Coller received the Robert J. and Claire Pasarow Foundation Award in 2005, the Warren Alpert Foundation Award in 2001 and a National Research Achievement Award from the American Heart Association in 1998. He is a member of the Institute of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences. Dr. Coller is a past president of the American Society of Hematology and currently is the founding president of the Society for Clinical and Translational Science.

    Click here for Dr. Coller's Publications

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Coller during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Scientific Advisory Board:

  • Chugai Pharmabody Research, Pte., Ltd.

Royalty Payments:

  • Accumetrics, Inc.; Janssen Biotech, Inc., formerly Centocor Biotech, Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Annenberg Building Floor 23rd Floor Room Room 23-92
1468 Madison Avenue
New York, NY 10029

Tel: 212-327-7494
Fax: 212-327-7493

Address

1230 York Avenue
The Rockefeller University
New York, NY 10065